About FAOD In Focus
FAOD In Focus is a program devoted to educating patients, caregivers, and doctors about FAOD. We aim to bring the FAOD community the most up-to-date information about the disease, diagnosis, treatment advances, and clinical opportunities.
The mission of FAOD In Focus is to provide a trusted, educational, and informational resource for patients, caregivers, and doctors, striving to lead the entire FAOD community in both understanding the disease and looking ahead toward a treatment that redefines long-term prognosis.
FAOD In Focus is owned by Ultragenyx Pharmaceutical Inc. Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company dedicated to bringing to market novel products for the treatment of rare and ultrarare diseases, with a focus on serious, debilitating genetic diseases. There are more than 7000 rare and ultrarare diseases in the world, but treatments (or treatment options) for only 400 of them.
The goal of Ultragenyx is to help people with unmet medical needs by working closely with patients, families, doctors, and patient organizations to understand how these diseases affect people’s lives, the advantages and disadvantages of any current treatments, and the hopes for potential new treatment options. Today, Ultragenyx is developing 4 potential treatments for 6 rare diseases. FAOD are included in these diseases.
Visit the Ultragenyx website to learn more.